TITLE

NOT ALL ANTIBODIES HAVE BEEN CREATED EQUAL: Antibodies validated for routinely processed tissue seldom apply to frozen tissue sections.

Maddalena M Bolognesi¹, Francesco Mascadri¹, Roberto Perego¹, Silvia Bombelli¹, Francesca M Bosisio², Giorgio Cattoretti^{1,3}

1 Pathology, Department of Medicine and Surgery, Università di Milano-Bicocca, Via Cadore 48, Monza 20900 (MI), Italy

2 Laboratory of Translational Cell and Tissue Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium

3 Dept. of Pathology, Ospedale San Gerardo, ASST-Monza, Via Pergolesi 33, Monza 20900 (MI) IT

FINANCIAL SUPPORT

This work has been supported by Departmental University of Milano-Bicocca funds and by a Fondazione Cariplo grant (2017-0577) to Prof. Roberto Perego. MMB is a PhD student in the DIMET program..

Mailing address: Prof. Giorgio Cattoretti, Anatomia Patologica, UNIMIB and Ospedale San Gerardo, Via Pergolesi 33, 20900, Monza (IT). Phone: +39 039-233-2551 (office); +30 02-6448-8068 (lab); FAX: +39 039-233-2548; e-mail: giorgio.cattoretti@unimib.it

RUNNING TITLE

Re-validated antibodies on frozen sections.

CONFLICT OF INTERESTS

The Authors have no conflict of interests to declare.

ABSTRACT

A customized context-dependent validation of antibodies for the prospective use, rather than a general stamp of validity, is required for reproducibility and data validity, besides the need of standardized reagents. In-situ antibody staining is a technique broadly used in experimental settings and human diagnostic practice. The first typically, but not exclusively uses lightly fixed material (cell smears, frozen sections), the second, routinely processed formalin-fixed, paraffin-embedded (FFPE) tissue. Differently from techniques based on tissue extraction, there is little awareness of the context-dependent constraints inherent with either type of in situ staining except that antigen masking associated with routine tissue processing limits the range of useful antibodies. We applied a panel of 126 antibodies validated for FFPE to lightly fixed (acetone, formalin) frozen sections and found that less than 30% performed conservatively with all fixations, 35% preferred one fixation over another, 13% gave non-specific staining, 23% did not stain at all. Individual antibody variegation of the paratope fitness for the differentially fixed antigen may be the cause. Re-validation of established antibody panels is required when applied to sections whose fixation and processing is different from the tissue where they have been initially validated.

INTRODUCTION

Over the last fifteen years, awareness of the frequent variability and unreliability of data caused by the use of non-standardized, not validated antibodies (Abs) in various types of immunoassays such as Western Blot (WB), Immunocytochemistry (ICC) and Immunohistochemistry/immunofluorescence (IHC/IF) (1-4), has suggested common guidelines for the correct use of these reagents. An International Working Group for Antibody Validation (IWGAV) convened in 2016 and published a proposal to ensure reproducibility and validity when using antibodies for immunolabeling (5). Five validation principles and criteria were proposed, based on: stain reduction upon genetic ablation of the target (“genetic”), comparison with an antibody-independent method (“orthogonal”), comparison of two different Abs against the same target (“independent antibody”), comparison with a “tagged protein expression” and mass spectrometry analysis of the immunocaptured protein (“IMS”). The suitability of each validation method for several applications, including in situ staining methods (ICC and IHC) was reported as well (5). Guidelines for antibody reporting in publications were published (3, 6) around the same time.

These suggested guidelines apply to very diverse subjects in many science fields, including Pathology. Surgical Pathologists in particular are using IHC in an highly regulated diagnostic settings, where pre-analytical, analytical and reporting rules need to be strictly defined, because of the human health implications of these assays (7). Surgical Pathology Departments may routinely use >200 different primary antibodies and introduce about 20 new antibodies a year (7), however the focus of the antibody/assay validation is on technical reproducibility across the caseload rather than on the antibody validation as intended by the International Working Group mentioned above. The antibody specificity for the target is a given assumption, often provided by the company supplying the antibody or the assay. On the other hand, the type of tissue target in Surgical Pathology is overwhelmingly FFPE tissue sections, whose pre-analytical variables are also highly regulated (8). The modifications of the protein targets in FFPE material and the performance of antibodies in such conditions have been extensively published and are the basis for a successful use of FFPE tissue for diagnostic, prognostic and theragnostic purposes (9-11). Because of the robustness of tissue processing and immunoanalysis, archived FFPE human material and Surgical Pathology techniques are also the most abundant and diffuse tools for translational and basic science research.

The IWGAV recommendations are that “approaches for antibody validation must be carried out in an application- and context-specific manner.” (5), suggesting that antibody validation must be independent for extractive (e.g. WB, immunoprecipitation) versus in-situ technique (ICC, IHC) on the basis of the different modifications that the protein target undergoes in each procedure (see Supplementary Table 1 in (5)). Although the IWGAV makes a distinction between ICC and IHC, reports on the requirement for an independent antibody validation on either type of tissue type are scanty at best, while the underlying assumption in the vast majority of publications is that an antibody good for FFPE must be good for a frozen section or a cell preparation as well and vice versa. The only caveat is that antigen masking in FFPE tissue makes it harder to find antibodies working on both types of tissues. A handful of groups (12-14) addressed in a systematic fashion the difference in antibody performance in FFPE versus lightly fixed frozen tissue section, these latter believed at that time to be the “golden standard” (12) to assess distribution, intensity and, ultimately, validity of an antibody. In those publications, the focus was on the differential antigen retention with each fixation protocol, rather than questioning the antibody specificity, which was a given predefined value, also because coming from the Surgical Pathology practice.

We have previously investigated the epitope specificity and binding requirements of a large number of antibodies for human FFPE material by applying them to swine routinely fixed

material (15). The results showed that about 50% did not react, despite complete identity of the epitope in both species. This may have occurred because of the fine requirement for some Abs of the conformation of the target side peptide chains not involved in the antigen binding (16) or because of non-identical juxtaposed adjacent proteins in the fixed complex. Of the Abs reacting with both species, we had evidence of species-specific negative effect of formalin fixation of BCL6, restricted to one antibody and not to others, while all did reacted on acetone-fixed frozen sections (15). In a separate investigation (11), we found that the epitopes for some antibodies were selectively destroyed by antigen retrieval (AR), possibly because of the conformational nature of the epitope.

These observations suggest that validated antibodies for FFPE sections may bear undisclosed paratope variations which may affect sensitivity, validity and usage when applied outside that context. Therefore we investigated a large panel of antibodies, validated on FFPE, on lightly fixed (acetone, formalin) frozen tissue sections. Antibodies for FFPE sections may detect linear epitopes (15) in a profoundly denatured protein mixture, thus we expected them to be working spectacularly on lightly fixed frozen material, but we found that this is quite often not the case.

MATERIALS AND METHODS

Human specimens

Fully anonymized human surgical specimen leftovers (pediatric tonsils, normal kidney, discarded serial sections from routinely processed formalin-fixed, paraffin-embedded (FFPE) material) were either snap-frozen in -80°C chilled isopentane (Merck Life Science S.r.l., Milano, Italy) or fixed overnight at RT in buffered 4% formaldehyde (Bio-Optica Milano Spa, Milano, Italy), processed through a graded ethanol gradient, then in xylene and embedded in molten paraffin for sectioning.

The study has been approved by the Institutional Review Board Comitato Etico Brianza, N. 3204, “High-dimensional single cell classification of pathology (HDSSCP)”, October 2019. Patients consent was obtained or waived according to article 89 of the EU general data protection regulation 2016/679 (GDPR) and decree N. 515, 12/19/2018 of the Italian Privacy Authority.

Antibody validation

A list with all the primary antibodies validated for FFPE use can be found in in Supplementary Table 1. The type of validation of each reagent was listed essentially according to Edfors et al. and Uhlén et al. (5, 17) and modified for tissue staining. The following criteria were used:

- Orthogonal: an antibody uniquely identifying a cell in the tissue whose high-dimensional phenotype (18, 19) corresponds to a cell described by single cell RNA sequencing (i.e transcriptomics) and bearing the transcript corresponding to the target is considered validated.
- Independent Antibody: A) two antibodies directed against two separate epitopes of the same protein and having an identical staining pattern and/or co-localizing by double IF or B) an antibody uniquely identifying a cell in the tissue whose high-dimensional phenotype corresponds to a cell whose phenotype is defined by a multidimensional flow cytometry panel, are considered validated
- Genetic: an antibody whose staining or absence of staining corresponds to a genetically engineered ectopic expression or absence of the target is considered validated
- Peptide Microarray: an antibody recognizing its unique peptide target on peptide microarrays (20, 21) is considered validated
- Cross-species: an antibody whose reactivity is conserved across genomic sequence variations in another species (15) is considered validated

We added an additional criterion, “historic”, for antibodies whose widespread use in multiple applications (e.g. CD20) strongly suggests validity, despite lacking one of the criteria listed above.

Evidence of validation not present in the published literature, either peer-reviewed papers or documentation from producers, was produced in house. Some antibodies were validated according to multiple criteria. Validated, FFPE-proof antibodies directed against the same protein can be used exchangeably on routinely processed sections, besides obvious variations in host species or isotype (22).

Representative iconography of the FFPE staining for each antibody can be viewed in published papers ((19, 23)), in (24) or at the Human Protein Atlas website (<https://www.proteinatlas.org/>).

Frozen tissue fixation

Frozen tissue blocks were sectioned at 5 µm thickness in a Leica CM1850 cryostat (Leica Microsystems GmbH, Wetzlar, Germany) at -20C. Sections were collected on positively charged slides (Menzel-Glaser Superfrost Plus; Bio-Optica Milano Spa).

Two fixation methods were chosen: in one, sections on slides were lifted from the cryostat, placed temporarily in a slide rack, immersed in acetone (Merck) at +4°C for 5 min, allowed the acetone to evaporate, stored at RT overnight in a damp-proof box; subsequently, the sections were either used the same day or stored wrapped in plastic foil at -20°C for later use.

In the second method, slides with the frozen section attached were immediately immersed in 4% buffered formaldehyde (FA), fixed at RT for 18h (overnight), then washed in Tris-containing buffer for formaldehyde quenching (25). These sections were stored at +4°C in 50 mM Tris HCl buffer pH 7.5, containing 0.01% Tween-20 (Merck) and 100 mM sucrose (TBS-Ts).

Previous published experiments (11) showed that fixation in excess of 30 min is required for tissue stabilization and epitope rescue upon AR and 48h or 72h fixation do not add additional masking, compared to overnight fixation, therefore we chose this latter fixation time for all the experiments.

Frozen sections were dipped for 5 min in 2.5% horse serum in TBS (Vector Laboratories, Burlingame, CA, USA) before use for Fc receptor blocking.

Antigen retrieval

Antigen retrieval (AR) was performed placing the sections in a 800 ml glass container filled with the retrieval solutions (10 mM EDTA in Tris-buffer pH 8, Merck), irradiate in a household microwave oven at full speed for 8 min, followed by intermittent electromagnetic radiation to maintain constant boiling for the set time, and cooling the sections to about 50 °C before use. We found that 20 min of AR on FA-fixed frozen sections did not produce any additional retrieval compared to 1 min or 5 min (not shown), thus a protocol comprising the 8 min preheating and 1 min AR was used throughout.

Immunolabeling.

Sections were processed for indirect immunohistochemistry or immunofluorescent labeling as previously described in detail (19, 23).

Briefly, the sections were incubated for 30 min with optimally diluted primary antibodies in combination of up to four (22), washed and counterstained with specific distinct fluorochrome-tagged secondary antibodies (23). The slides, counterstained with DAPI and mounted, were scanned on an S60 Hamamatsu scanner (Nikon, Italia) at 20x magnification (23). Optimal exposure time for each antibody-fluorochrome combination was set in advance on FFPE and validated over multiple samples in a multiplex experiment on routinely processed material ((18) and not shown). Quadruple simultaneous IF staining guarantees internal control for effective

staining. Dubious results were confirmed in single stain IHC. The vast majority of the tests were done on tonsil sections, which constitute the optimal positive control for a panel in which anti-leukocyte antibodies are overrepresented. Acetone-fixed, formalin-fixed and formalin-fixed AR treated frozen sections were all processed simultaneously.

Results were scored semi-quantitatively (neg, +/-, +, ++, +++) and qualitative staining features (diffuse, non-specific staining, etc.) were annotated.

Preparation of immunofluorescent images for image analysis.

Single .ndpi images for each case were saved as .tiff files and autofluorescence (AF) was subtracted (23). Grayscale images were inverted, brightness and contrast adjusted with the default ImageJ function (26), simultaneously processing a stack of three experimental sets (acetone, FA, FA>AR) before producing individual images.

RESULTS

The overwhelming majority of antibodies tested were selected for being reactive with AR-treated FFPE sections (118/126), yet 8 (6.3%) selectively failed to stain acetone fixed sections and additional 8 had minimal reactivity compared to FA fixed sections.

Fourteen, including these latter eight, required formalin fixation to be detected (11.1%) (Table 1, Fig. 1 and labelled “FA dependent” in Supplementary Table 1) and AR was able to enhance the staining in only three of them.

FA fixation did reduce epitope detectability in a quarter of the cases and abolished the reactivity in as many as 24 cases (19.8%) (“FA blocked” in Table 1 Fig. 1 and Supplementary Table 1); in all these instances, AR rescued the optimal reactivity.

The epitope composition of the “FA blocked” antibodies was available for 5 Abs only and short enough to be informative in one (CD3-12; ERPPPVPNPDYEPC). The epitope contained no lysine, the topmost aminoacid bound by formaldehyde, yet was sensitive to FA fixation on frozen sections.

A group of 17 abs (13.5%) had immunoreactivity either selectively elicited by AR treatment (12 Abs) or abolished by the heat treatment. We defined those as “conformational” because of a possible disruption (or creation) of an epitope by altering the conformation of one or more protein loops generating the epitope (Table 1, Fig. 1 and Supplementary Table 1)

A group of 6 Abs (4.8%) we named “miscellaneous” (Table 1, and Supplementary Table 1) contained Abs behaving differently than the previous groups and were composed mostly of Abs reacting with acetone-fixed sections only. One antibody (GZMB) labelled selectively FA-fixed frozen sections.

Twenty nine Abs (22.8%) did not stain any type of lightly fixed sections.

The remaining Abs (35/126; 27.8%) had conserved reactivity across the three preparations: acetone fix, FA fix, FA>AR (“conserved”; Table 1, Fig. 1 and Supplementary Table 1).

Whenever the protein distribution was shared with cells of diverse origin (e.g. podoplanin on endothelium, basal epithelium and follicular dendritic cells), differential response to the fixation protocols was noted according to the cell type. As an example, only the endothelial staining of Podoplanin (Fig. 1) conserved an equivalent intensity across the three fixation protocols. For some protein, a loss of the target from sections in acetone fixed tissue was noticed (e.g. LYZ, S100AB)

Spurious reactivity, either due to non-specific, background staining or to discrete unrelated targets (Fig. 1) was detected in 17 instances (13.4%), 10 of them (7.8%) in FA fixed sections.

In 19 instances, the same protein was tested with multiple independent antibodies which showed in all instances but two individual variations in staining pattern (Supplementary Table 1).

Because of the antibody panel choice, biased toward leukocyte antigens, most Abs did not react with swine FFPE tissue (15), thus no epitope variation information could be obtained.

DISCUSSION

A minority of antibodies validated for the use on FFPE material apply for the use on frozen sections, formalin- or acetone fixed. The most likely reason for such unexpected results may lie in the subtle requirement of the paratope for an unique epitope binding environment, composed not just of the epitope, but also of the neighboring residues on the protein sequence (16) or of adjacent unrelated proteins and their post-translational modifications (27). Such epitope microenvironment is affected by the fixation method and, when applied, by further denaturation provided by high heat.

So far, the burden of the proof has been put on the antigen and its modification during fixation. Our investigation however started from anti-peptide antibodies validated on the new “gold standard”, FFPE material (12), went back to the frozen tissue perceived as containing native proteins, and has unveiled how context-dependent the use of Abs for in situ detection can be.

Differently from previous published work (12-14), the use of multiple antibodies for the same target (35% of the panel) has disclosed a remarkably heterogeneous staining ability within the same target across the experimental conditions, suggesting that the source of variance is the paratope variegation, rather than epitope.

It has also shown evidence of the persistence of the antigen in the tissue with that particular fixation condition, indirectly re-validating the use of acetone-fixed or formalin-fixed frozen sections as “alternative gold standards” for antigen detection in tissue. Only a couple of antigens may have been lost from acetone-fixed sections, as previously published (12, 13).

The recommendation to validate and use antibodies limited to the technique employed (Western Blot, immunoprecipitation, immunohistochemistry, etc.) (5, 17) may now be made in a more detailed fashion also for immunological in situ techniques, distinguishing frozen sections from FFPE material, and within frozen sections, whether acetone or FA is used and if AR is required. Particularly worrisome for staining reliability across fixations is the presence, albeit small, of unrelated discrete reactivity (e.g. CD8 on epithelia; this report and (28, 29)) or the variegated effect of treatment on epitopes shared across diverse cell types (e.g. Podoplanin, PDL1) (Fig. 1).

The major bias of this study is the antibody choice, which was guided by the validity on routinely processed tissue sections, being only 9 of the selected Abs not reactive on FFPE. Another bias is the abundance of mouse non-IgG1, non-rabbit antibodies (42%), due to the multiplexing

staining strategy (22), selection which however may have highlighted the problem by diversifying, besides the immunizing epitope, the host view of the immunogen.

Collectively, these data suggest that antibody binding may be very dependent on tissue fixation and processing in a subtle and unexpected fashion, affecting binding and specificity for the target.

ACKNOWLEDGEMENTS

This work has been supported by the Departmental University of Milano-Bicocca funds and by a Fondazione Cariplo grant (2017-0577) to Prof. Roberto Perego. MMB was funded by a Cariplo grant (2017-0577) and is a PhD student in the DIMET PhD Program call XXXV of the Department of Medicine and Surgery of the University of Milano-Bicocca since November 2019. We wish to thank Carlo Parravicini for suggestions, Lorella Riva and Loredana Tusa for expert help in histopathology.

AUTHOR'S CONTRIBUTIONS

GC and MMB equally designed the experiments.

MMB devised the image analysis algorithms, performed visual and digital image analysis as well as bioinformatic evaluation.

FM and SB performed immunostaining experiments.

FMB and RP provided essential reagents.

MMB, FMB and GC wrote the manuscript.

All authors have read and approved the final manuscript.

COMPETING INTEREST STATEMENT

The authors declare they have no competing interests.

TABLE LEGENDS

Table 1

Summary table of the staining results, grouped by category.

FIGURE LEGENDS

REFERENCES

1. Bradbury A, Plückthun A. Reproducibility: Standardize antibodies used in research. *Nature*. 2015;518(7537):27-9. doi: 10.1038/518027a. PubMed PMID: 25652980.
2. Howat WJ, Lewis A, Jones P, Kampf C, Ponten F, van der Loos CM, Gray N, Womack C, Warford A. Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. *Methods*. 2014;70(1):34-8. doi: 10.1016/j.ymeth.2014.01.018. PubMed PMID: 24525140; PubMed Central PMCID: PMC4240800..
3. Helsby MA, Fenn JR, Chalmers AD. Reporting research antibody use: how to increase experimental reproducibility. *F1000Research*. 2013;2:153. doi: 10.12688/f1000research.2-153.v2. PubMed PMID: 24358895; PubMed Central PMCID: PMC43829129.
4. Pradidarcheep W, Labruière WT, Dabhoiwala NF, Lamers WH. Lack of specificity of commercially available antisera: better specifications needed. *The Journal of Histochemistry and Cytochemistry*. 2008;56(12):1099-111. doi: 10.1369/jhc.2008.952101. PubMed PMID: 18796405; PubMed Central PMCID: PMC2583905.
5. Uhlén M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T. A proposal for validation of antibodies. *Nature methods*. 2016. doi: 10.1038/nmeth.3995. PubMed PMID: 27595404.
6. Hewitt SM, Baskin DG, Frevert CW, Stahl WL, Rosa-Molinar E. Controls for Immunohistochemistry: The Histochemical Society's Standards of Practice for Validation of Immunohistochemical Assays. *Journal of Histochemistry & Cytochemistry*. 2014. doi: 10.1369/0022155414545224. PubMed PMID: 25023613.
7. Stuart LN, Volmar KE, Nowak JA, Fatheree LA, Souers RJ, Fitzgibbons PL, Goldsmith JD, Astles JR, Nakhleh RE. Analytic Validation of Immunohistochemistry Assays: New Benchmark Data From a Survey of 1085 Laboratories. *Archives of pathology & laboratory medicine*. 2017. doi: 10.5858/arpa.2016-0559-CP. PubMed PMID: 28557616.
8. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. *Arch Pathol Lab Med*. 2020;144(5):545-63. doi: 10.5858/arpa.2019-0904-SA. PubMed PMID: 31928354.
9. Stumptner C, Pabst D, Loibner M, Viertler C, Zatloukal K. The impact of crosslinking and non-crosslinking fixatives on antigen retrieval and immunohistochemistry. *New biotechnology*. 2019;52:69-83. doi: 10.1016/j.nbt.2019.05.003. PubMed PMID: 31082574.
10. Hötzel KJ, Havnar CA, Ngu HV, Rost S, Liu SD, Rangell LK, Peale FV. Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry. *Journal of Histochemistry & Cytochemistry*. 2019;67(5):309-34. doi: 10.1369/0022155419832002. PubMed PMID: 30879407; PubMed Central PMCID: PMC6495489.
11. Scalia CR, Boi G, Bolognesi MM, Riva L, Manzoni M, DeSmedt L, Bosisio FM, Ronchi S, Leone BE, Cattoretto G. Antigen Masking During Fixation and Embedding, Dissected. *Journal of*

- Histochemistry & Cytochemistry. 2017;65(1):5-20. doi: 10.1369/0022155416673995. PubMed PMID: 27798289; PubMed Central PMCID: PMC5256198.
12. Shi S-R, Liu C, Pootrakul L, Tang L, Young A, Chen R, Cote RJ, Taylor CR. Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry. *American Journal of Clinical Pathology*. 2008;129(3):358-66. doi: 10.1309/7CXUYXT23E5AL8KQ. PubMed PMID: 18285257.
13. Yamashita S, Okada Y. Application of heat-induced antigen retrieval to aldehyde-fixed fresh frozen sections. *The Journal of Histochemistry and Cytochemistry*. 2005;53(11):1421-32. doi: 10.1369/jhc.4A6579.2005. PubMed PMID: 16046672.
14. Hira VVV, de Jong AL, Ferro K, Khurshed M, Molenaar RJ, Van Noorden CJF. Comparison of different methodologies and cryostat versus paraffin sections for chromogenic immunohistochemistry. *Acta Histochem*. 2019;121(2):125-34. doi: 10.1016/j.acthis.2018.10.011. PubMed PMID: 30454859.
15. Scalia CR, Gendusa R, Basciu M, Riva L, Tusa L, Musarò A, Veronese S, Formenti A, D'Angelo D, Ronzio AG, Cattoretti G, Bolognesi MM. Epitope Recognition in the Human-Pig Comparison Model on Fixed and Embedded Material. *Journal of Histochemistry & Cytochemistry*. 2015;63(10):805-22. doi: 10.1369/0022155415597738. PubMed PMID: 26209082.
16. Janes KA. Fragile epitopes-Antibody's guess is as good as yours. *Sci Signal*. 2020;13(616). doi: 10.1126/scisignal.aaz8130. PubMed PMID: 31992582.
17. Edfors F, Hober A, Linderbäck K, Maddalo G, Azimi A, Sivertsson A, Tegel H, Hober S, Szigarty CA-K, Fagerberg L, von Feilitzen K, Oksvold P, Lindskog C, Forsström B, Uhlén M. Enhanced validation of antibodies for research applications. *Nature Communications*. 2018;9(1):4130. doi: 10.1038/s41467-018-06642-y. PubMed PMID: 30297845; PubMed Central PMCID: PMC6175901.
18. Bosisio FM, Antoranz A, van Herck Y, Bolognesi MM, Marcelis L, Chinello C, Wouters J, Magni F, Alexopoulos L, Stas M, Boecxstaens V, Bechter O, Cattoretti G, van den Oord J. Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. *Elife*. 2020;9. doi: 10.7554/eLife.53008. PubMed PMID: 32057296; PubMed Central PMCID: PMC67053517.
19. Manzoni M, Bolognesi MM, Antoranz A, Mancari R, Carinelli S, Faretta M, Bosisio FM, Cattoretti G. The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas. *Sci Rep*. 2020;10(1):702. doi: 10.1038/s41598-020-57627-1. PubMed PMID: 31959856; PubMed Central PMCID: PMC6971074.
20. Sjöberg R, Mattsson C, Andersson E, Hellström C, Uhlén M, Schwenk JM, Ayoglu B, Nilsson P. Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling. *New biotechnology*. 2016;33(5 Pt A):582-92. doi: 10.1016/j.nbt.2015.09.002. PubMed PMID: 26417875.
21. Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, Hoang T, Fu W, Min L, Lan Z-S, Wang F, Mull L, He W-W. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. *BMC Biotechnology*. 2012;12(1):88. doi: 10.1186/1472-6750-12-88. PubMed PMID: 23171216; PubMed Central PMCID: PMC3526464.

22. Cattoretti G, Bosisio F, Marcelis L, Bolognesi MM. Multiple Iterative Labeling by Antibody Neodeposition (MILAN): Nature Research; 2019 [updated September 25, 2019]. Available from: <https://protocolexchange.researchsquare.com/article/nprot-7017/v5>.
23. Bolognesi MM, Manzoni M, Scalia CR, Zannella S, Bosisio FM, Faretta M, Cattoretti G. Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections. *Journal of Histochemistry & Cytochemistry*. 2017;65(8):431-44. doi: 10.1369/0022155417719419. PubMed PMID: 28692376.
24. Bolognesi MM, Bosisio F, Manzoni M, Schapiro D, Tagliabue R, Faretta M, Parravicini C, Haberman AM, Cattoretti G. The landscape of S100B+ and HLA-DR+ dendritic cell subsets in tonsils at the single cell level via high-parameter mapping. [Preprint]. In press 2018. doi: <https://doi.org/10.1101/369983>
25. Sutherland BW, Toews J, Kast J. Utility of formaldehyde cross-linking and mass spectrometry in the study of protein-protein interactions. *Journal of mass spectrometry : JMS*. 2008;43(6):699-715. doi: 10.1002/jms.1415. PubMed PMID: 18438963.
26. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nature methods*. 2012;9(7):671-5. doi: 10.1038/nmeth.2089. PubMed PMID: 22930834.
27. Bogen SA, Vani K, Sompuram SR. Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced cross-links. *Biotechnic & histochemistry : official publication of the Biological Stain Commission*. 2009;84(5):207-15. doi: 10.3109/10520290903039078. PubMed PMID: 19886757.
28. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, Cotsarelis G. The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. *J Cell Sci*. 1998;111 (Pt 21):3179-88. PubMed PMID: 9763512.
29. Mason DY, Cordell JL, Gaulard P, Tse AG, Brown MH. Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence. *Journal of clinical pathology*. 1992;45(12):1084-8. doi: 10.1136/jcp.45.12.1084. PubMed PMID: 1479035; PubMed Central PMCID: PMC495002.

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLE 1

List of primary antibodies.

Abbreviations:

Species: Rb= rabbit; RbMab= rabbit monoclonal ab; g1, g2a, g2b, g3= mouse isotypes.

FFPE: yes= working on routinely processed material.

RRID: Resources Identification Portal identifier (<https://scicrunch.org/resources>)

Classification: conformational= conformational epitope; conserved= staining conserved over fixation types; FA blocked= reactivity blocked by FA fixation; FA dependent= staining depends on FA fixation; negative= no staining; misc= miscellaneous behaviour, mostly Acetone only, not comprised in the previous classification. Spurious= spurious, non-specific reactivity present.

Validation: type of antibody validation as described in M&M.

Bolognesi MM et al. Re-validated antibodies on frozen sections.

TABLE 1

Reactivity	Acetone	FA	FA > AR	N. Abs	%	Note
conserved	pos	pos	pos	35	27.8%	Reactivity preserved on all fixations
FA blocked	pos	neg	pos	25	19.8%	Inactivated by FA fixation (rescued by AR)
FA dependent	neg	pos	pos	14	11.1%	Requires FA fixation
conformational	pos	pos	neg	17	13.5%	Heat-induced appearance/disappearance
	neg	neg	pos			
misc	pos/neg	neg/pos	neg	6	4.8%	Mostly Pos in Acetone fixed only
neg	neg	neg	neg	29	23.0%	No reactivity
Total				126		

NOT ALL ANTIBODIES HAVE BEEN CREATED EQUAL: Antibodies validated for routinely processed tissue seldom apply to frozen tissue sector Maddalena M Bolognesi, Francesco Mascadi, Roberto Perego, Silvia Bombelli, Francesca M Bosio, Giorgio Cattorelli

Species	Ab	clone	Source	FPERRID	Ac	FA	FA> AR	NOTES			Classification	Spurious re	validation
								Ac	FA	FA> AR			
Rat	AID	MAU-2	Thermo	yes	1069583	neg	neg				neg		
RbMab	AXL	C89E7	CST	yes	11217435	++	+	endothel +?	sparse Lymphs, endoth	+	neg		genetic
g1	bcl-2	Bcl-2-100	Merck	yes	258541	+++	+++				conserved		genetic
g3	BCL6	D-8	SCBT	yes	2063455	+++	++				conserved		independent Ab
Rat	Blimp1/PRDM1	6D3	SCBT	yes	628168	note	+/-	background			FA blocked		independent Ab, historic
g1	BM1	F8	Millipore	yes	309865	neg	neg				neg		
g1	CD10	NCL-CD10-L-270	Leica-Microsystem	yes	442048	++	++				neg		cross-species
RbMab	CD103	EP206	Bio SB	yes	626859	neg	neg				FA blocked		
g1	CD11c	B-6	SCBT	yes	395454	+++	+++				neg		
g2A	CD123	7G3	BD Pharmingen	no	10555271	neg	neg				conserved		orthogonal
g2B	CD123	NCL-L-CD123	Leica-Microsystem	yes	244341	+++	+++				conformational		orthogonal, historic
g1	CD133	AC133	Millipore	yes	781932	+/-	background				conserved		orthogonal
g1	CD14	5A3B11B5	SCBT	yes	1078467	neg	neg				conformational	spurious	independent Ab
Rb	CD14	poly	Merck	yes	2201805	+++	++				neg		independent Ab
RbMab	CD141	EPR4051	Abcam/Epitomics	yes	2201940	neg	neg				FA blocked		independent Ab
g2A	CD141	D-3	SCBT	yes	563508	neg	neg				conformational		independent Ab
g2A	CD16	2H7	Leica-Microsystem	yes	626933	+++	+++				neg		independent Ab
g1	CD163	GH161	SCBT	no	626932	+++	neg				conformational		independent Ab
g1	CD163	RM3/1	SCBT	no	10982556	neg	neg				FA blocked		independent Ab
g1	CD163	10D6	Thermo	yes	626957	+++	+++				conformational		independent Ab
g1	CD1A	O10	SCBT	yes	2623067	neg	neg				neg		orthogonal
g1	CD1c	2F4	Origene	yes	2623049	neg	neg				neg		orthogonal
g1	CD1c	2D4	Origene	yes	2629056	neg	neg				neg		orthogonal
g1	CD1c	UMAB46	Origene	yes	2073673	neg	neg				neg		peptide microarray, orthogonal
g2A	CD2	B-8	SCBT	yes	2282030	+++	+++				neg		
g2A	CD20	L26	Dako	yes	1078467	neg	neg				conserved		historic
g2B	CD206	# 685645	R&D	yes	1078467	neg	neg	non-specific			FA dependent	spurious	
Rb	CD207	langerin	poly	Merck	yes	1121259	+++				neg		historic
g2A+2B	CD21	2C9 + A3	Thermo + SCBT	yes	11155136	+	++				FA blocked		historic
RbMab	CD22	SP104	Merck	yes	61258	+++	++				conserved		
g2A	CD23	UMAB101	Origene	yes	2629143	neg	neg				conformational		
g1	CD246	B1/35	BD Pharmingen	yes	1121259	+++	+++				FA blocked		
RbMab	CD27	EPR8569	Abcam/Epitomics	yes	61258	+++	++				conserved		
g1	CD271	NGFR 5	Neomarkers	yes	259074	+	neg				conserved		historic
Rb	CD3	poly	Merck	yes	1120361	+++	+/-				FA blocked		independent Ab, cross-species
Rat	CD3	CD3-12	SCBT	yes	149922	+++	note				FA blocked		independent Ab
RbMab	CD3	SP7	Thermo	yes	2335683	+++	+	endothel. stromal			conserved	spurious	independent Ab, historic
g1	CD30	BerH2	SCBT	yes	10988551	+++	+/-				FA blocked		independent Ab, historic
g2A	CD30	CON6D/ C2	Thermo	yes	244165	+++	neg				FA blocked		independent Ab
g1	CD303	AC144	Millipore	no	1078467	neg	neg	non-specific	non-specific	non-specific	neg	spurious	independent Ab
Rb	CD303	poly	Merck	yes	2799462	neg	neg	panEpith	GC & DC (?)		neg	spurious	independent Ab
g1	CD303	124b3.13	Dendritics	yes	629040	+	+++				neg		independent Ab
RbMab	CD30v	E4L41	CST	yes	2103735	neg	note				neg		independent Ab
g1	CD31	JC70	SCBT	yes	631133	+++	+/-				conserved		historic
g2B	CD32abc	B-4	SCBT	yes	631133	+++	+/-	nuclear bkgnd			neg	spurious	
g3	CD34	43A1	SCBT	yes	1078467	neg	neg				conformational		independent Ab
g2B	CD39	IMG17B5F11	Abcam/Epitomics	yes	627055	+++	neg				neg		
RbMab	CD4	EPR6855	Abcam/Epitomics	yes	400154	+++	+++				conformational		independent Ab
g1	CD4	MT310	SCBT	no	2075324	+/-	neg				FA blocked		independent Ab
g1	CD45	Hle-1 2D1	BD Pharmingen	no	627083	+++	++				conformational		independent Ab, historic
g1	CD45+43	PD7/26 + 35-Z6'	BioLegend	yes	2075324	+/-	neg				conserved		independent Ab, historic
g2A	CD45R0	UCHL-1	SCBT	yes	627127	note	note				conserved		independent Ab, historic
g1	CD5	CD5/54/F6	SCBT	yes	627127	note	note	endoth. basal sq	endothelium	endothelium	neg	spurious	historic
g1	CD56	123C3.D5	SCBT	yes	2623718	neg	note				conformational	spurious	independent Ab, historic
g1	CD64	OT1D3	Origene	yes	627158	+++	++				conserved		independent Ab, historic
g1	CD68	KP1	SCBT	yes	10979558	neg	+/-				FA dependent		independent Ab
g3	CD68	PGM1	Thermo	yes	1078467	neg	neg				neg		orthogonal
Rb	CD69	poly	Merck	yes	1078467	+	neg				neg		
Rb	CD7	poly	Merck	yes	1120686	++	+++				FA blocked		orthogonal
g1	CD74	UMAB231	Origene	yes	10897816	+++	+++				conserved		independent Ab, cross-species
g1	CD79a	JCB117	SCBT	yes	1120718	+++	note				conserved		independent Ab
g1	CD8	C8/144B	SCBT	yes	831132	neg	neg	epith. basal layer, lymphs very weak			neg	spurious	independent Ab, historic
g2B	CD83	F-5	SCBT	yes	1078467	neg	neg				conformational		independent Ab
Gt	CD86	poly	Merck	yes	627211	+/-	neg				neg		
g1	CD8beta	F5	SCBT	yes	61869	+++	++	non-specific	non-specific	non-specific	FA blocked	spurious	independent Ab
g1	CDKN1B p27	DCS-72.F6	Neomarkers	yes	1078467	+/-	neg	pan epithelial			conserved	spurious	orthogonal
Rb	CLEC10A	poly	Merck	yes	1078467	neg	neg				neg		orthogonal
Gt	CLEC9A	poly	Merck	yes	2537779	neg	neg				conformational		orthogonal
g1	CLEC9A	14N8D7	Thermo	no	1078467	+/-	neg				neg		orthogonal
Rb	cMAF	poly	Merck	yes	1078467	+++	++				FA dependent		
Rb	cREL	poly	Merck	yes	1078467	+++	++				FA blocked		orthogonal
Gt	CXCL13	poly	Merck	yes	2292654	+++	note				conserved		independent Ab
g2B	CXCR5	#51505	R&D	yes	1078467	neg	neg	interstitium			FA blocked	spurious	
Rb	EOMES	poly	Merck	yes	445284	++	neg				neg		
g1	FoxP3	236A/E7	Abcam/Epitomics	yes	1078467	neg	neg				FA blocked		independent Ab
Gt	GATA3	poly	Merck	yes	1078467	neg	neg				neg		
g2A	GZMB	GRB7	BioLegend	yes	1078467	neg	+++				misc		historic
g2B	GZMK	GM6C3	SCBT	no	1841955	+/-	neg				conserved		
g3	Histone H3	1D8	Merck	yes	400289	+++	+++				conformational		
g1	HLA-DR	L243	BD Pharmingen	no	1125217	+++	+++	pan-cell			conformational		orthogonal, historic
g2B	HLA-DR	SPM288	SCBT	yes	neg	neg	neg				conserved		orthogonal
RbMab	ID1	BCH-1/195-14	Biocheck	yes	neg	neg	neg				neg		genetic
RbMab	ID2	BCH-3/9-2-8	Biocheck	yes	note	+++	++	cytoplasmic pos			FA dependent	spurious	genetic
RbMab	IDO	D5J4E	CST	yes	2626818	neg	neg				neg		
Gt	IgD	poly	Merck	yes	1078467	+++	+++				conserved		independent Ab
Rat	IRF4	3E4	SCBT	yes	2127138	+/-	+				conserved		independent Ab
Gt	IRF4	poly	Merck	yes	1078467	+/-	+++				FA dependent		independent Ab, cross-species
g2B	IRF8	E-9	SCBT	yes	10850401	+/-	+++				FA dependent		independent Ab
Rb	IRF8	poly	Merck	yes	1078467	neg	+/-				FA dependent		independent Ab, cross-species
Gt	kappa	poly	Merck	yes	1078467	+/-	+++				conserved		independent Ab, orthogonal
RbMab	Ki-67	SP6	Thermo	yes	2335745	++	+++				conserved		independent Ab, historic
g2A	Ki-67	UMAB107	Origene	yes	2629145	+++	+++				conserved		independent Ab
g1	Ki-67	MIB3	J.Gerdies	yes	776102	++	neg				conserved		independent Ab, historic
g1	LAG3	11E3	Abcam/Epitomics	yes	1078467	+/-	++				misc		independent Ab
Rb	lambda	poly	Merck	yes	10991107	+++	neg	selected areas			conserved		independent Ab, orthogonal
g2A	LEF1	B-10	SCBT	yes	1078467	+++	+++				FA blocked		
Gt	LYVE1	poly	Merck	yes	1078467	+/-	+++				conserved		
Rb	LYZ	poly	Merck	yes	1078467	+/-	+++				FA dependent		historic
Rb	MX-1	poly	Merck	yes	1078467	neg	neg				neg		orthogonal
RbMab	MYC	EP121	Merck	yes	1078467	neg	neg				FA blocked		independent Ab
g1	NFKB1 p50	E-10	CST	yes	neg	neg	neg				neg		orthogonal
g2A	NFKB2 p52	C-5	SCBT	yes	626897	+++	neg	diffuse bkgnd			FA blocked	spurious	orthogonal
g1	OX40	Ber-ACT35	SCBT	yes	2236668	+++	+/-				FA blocked		genetic, independent Ab
Rat	Pax5	1H9	Merck	yes	1078467	neg	neg				conserved		independent Ab
Rb	PD-L1	pool	BioLegend	yes	627143	neg	++	panEpith, low on Macs		Similar to Ac	conserved	spurious	peptide microarray, historic
g2A	PD1 pool	UMAB197 + UMAB199	BioLegend	yes	10920577	note	note	BasalEp stronger			FA blocked		peptide microarray, independent Ab
Rat	PNAAd	MECA-79	SCBT	yes	395335	neg	neg				FA dependent		orthogonal
Rat	Podoplanin	NZ-1.2	LSBio	yes	1078467	neg	neg				conserved		orthogonal
g2A	PU1	G148-74	BD Pharmingen	yes	627143	neg	++				neg		independent Ab, historic
g1	PU1pool	B-9 + C-3	BioLegend	yes	neg	+	+++				FA blocked		independent Ab
Rat	RBPJ	3E2	E. Klemmer	yes	neg	+	+++				FA dependent		
g2A	RORC	6F3.1	Abcam/Epitomics	yes	neg	neg	neg				neg		
Rb	S100AB	poly	Dako	yes	neg	+/-	+				FA dependent		independent Ab, historic

Species	Ab	clone	Source	FPERRID	Ac	FA	FA> AR	NOTES			Classification	Spurious re:	validation
								Ac	FA	FA> AR			
g2A	SOX9	CL0639	Merck	yes	2665670	neg	+++				conformational		
g1	TBET	O4-46	BD Pharmingen	yes		+/-	+++	heterogeneous			FA dependent		
RbMab	TCF4	NCI-R159-6	Abcam/Epitomics	yes	2714172	+++	++				conserved	orthogonal	
Gt	TCF7	poly	Merck	yes	1078467	+++	neg				FA blocked		
g1	TCRd	H-41	SCBT	yes	1130061	neg	neg				neg	historic	
Gt	TIM3	poly	Merck	yes	1078467	+++	+				conserved	orthogonal	
Rat	TOX1	NAN448A	Abcam/Epitomics	yes		neg	++				FA dependent	genetic	
g2B	TP53	DO-7	Dako	yes		neg	neg				conformational	independent Ab	
RbMab	VISTA	D1L2G + D5L5T	CST	yes		++	neg				FA blocked	orthogonal	
Gt	vWF	poly	Merck	yes	1078467	+++	+++				conserved	cross-species, historic	
Rb	ZEB1	poly	Merck	yes	1078467	+++	note			pan nuclear	misc	spurious	cross-species
g2A	ZEB1	3G6	LeBio	yes	2572969	note	+++	non-specific			FA dependent	spurious	cross-species